Cajanin has potential hypolipidemic effects,possibly via up-regulating the ABCA1 protein expression,subsequently resulting in increased macrophage cholesterol efflux and RCT, it can significantly improve basal glucose uptake in HepG2 cells, its improving effect is concentration dependent, it exhibits effects stronger than that of rosiglitazone, which has been used as an antidiabetic drug.
Molekulargewicht:
300.26
CAS Nummer:
[32884-36-9]
Formel:
C16H12O6
Target-Kategorie:
Tyrosinase|||ERK|||MEK|||Akt
TN1462
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
